EXPRESS-ZERTIFIKAT - ZURICH INSURANCE/SWISS RE/ROCHE GS Stock

Certificat

DE000SH9ZFK6

Market Closed - Deutsche Boerse AG 11:01:54 2024-05-23 am EDT
101.1 EUR +0.23% Intraday chart for EXPRESS-ZERTIFIKAT - ZURICH INSURANCE/SWISS RE/ROCHE GS
Current month+2.16%
1 month+1.64%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-23 101.1 +0.23%
24-05-22 100.9 -0.29%
24-05-21 101.2 -0.16%
24-05-20 101.3 +0.07%
24-05-17 101.3 -0.25%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 11:01 am EDT

More quotes

Static data

Product typeOther Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Société Générale Société Générale
WKN SH9ZFK
ISINDE000SH9ZFK6
Date issued 2023-08-03
Strike 267 CHF
Maturity 2025-02-03 (256 Days)
Parity 0.27 : 1
Emission price 1,000
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 103.2
Lowest since issue 96.92
Spread 12.4
Spread %1.21%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
232.1 CHF
Average target price
279.8 CHF
Spread / Average Target
+20.57%
Consensus